Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | MGAM | O43451 | 3/20 | 0.49 |
| ▸ | SI | P14410 | 3/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6683335 | 0.81 | GAA (0.52) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL1369785 | 0.81 | MAOB (0.49) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL10605737 | 0.79 | GAA (0.46) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL3281348 | 0.78 | MAOB (0.50) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL9227196 | 0.78 | GAA (0.49) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL28918556 | 0.75 | HSD17B10 (0.51) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL28918554 | 0.75 | GAA (0.50) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL7022121 | 0.71 | MAOB (0.50) | GAAKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL17579563 | 0.71 | CYP2A6 (0.55) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL9226988 | 0.68 | ADRB1 (0.46) | GAAMGAMSIMGAM2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-1156999-B1 | METHOD FOR THE PREPARATION OF A CHIRAL-BETA-AMINO ESTER | SEARLE LLC (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040127477-A1 | Heterocyclic glycyl beta-alanine derivatives | G. D. SEARLE & CO. (US) | 2004-07-01 | — | — | US | disclosed |
| US-6689754-B1 | PIPERIDINE OR PYRIDINE DERIVATIVES; ALPHA V BETA 3 INTEGRIN ANTAGONISTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | disclosed |
| US-20030050250-A1 | Alpha v beta 3 integrin antagonists in combination with chemotherapeutic agents | PHARMACIA CORPORATION | 2003-03-13 | — | — | US | disclosed |
| US-6372719-B1 | 1,4,5,6-TETRAHYDRO-5-HYDROXYPYRIMIDIN-2-AMINE DERIVATIVES ARE ADMINISTERED IN MIXTURE; ANTITUMOR AND ANTICARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 2002-04-16 | — | — | US | disclosed |
| EP-1161280-A1 | USE OF AN INTEGRIN ANTAGONIST AND A CHEMOTHERAPEUTIC AGENT IN THE TREATMENT OF NEOPLASIA | G.D. Searle & Co. (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1156999-A1 | METHOD FOR THE PREPARATION OF A CHIRAL-BETA-AMINO ESTER | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| EP-1070060-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. Searle & Co. (US) | 2001-01-24 | — | — | EP | disclosed |
| EP-1060164-A1 | META-AZACYCLIC AMINO BENZOIC ACID COMPOUNDS AND DERIVATIVES THEREOF BEING INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000051686-A1 | USE OF INTEGRIN ANTAGONIST AND A CHEMOTHERAPEUTIC AGENT IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051968-A1 | METHOD FOR THE PREPARATION OF A CHIRAL-BETA-AMINO ESTER | G.D. SEARLE & CO. (US) | 2000-09-08 | — | — | WO | disclosed |
| US-6100423-A | Amino benzenepropanoic acid compounds and derivatives thereof | G. D. SEARLE & CO. (US) | 2000-08-08 | — | — | US | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| US-6013651-A | ANTITUMOR AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; SKIN DISORDERS | G. D. SEARLE & CO. (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1999052896-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999044994-A1 | META-AZACYCLIC AMINO BENZOIC ACID COMPOUNDS AND DERIVATIVES THEREOF BEING INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-09-10 | — | — | WO | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050250-A1 | Alpha v beta 3 integrin antagonists in combination with chemotherapeutic agents | ITGAV, ITGB3, ITGB1 | GAA 2288/4885MGAM 4329/4885SI 2251/4885 |
| US-20040127477-A1 | Heterocyclic glycyl beta-alanine derivatives | ITGB3, ITGAL, ITGB1 | GAA 133/4885MGAM 1688/4885SI 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.